An actual investor asked me to look at the lieHUB board
An actual investor asked me to look at the lieHUB board because one of the chief multi-identity bashers was lying again about the company, and quoted one of my posts.
It is beyond funny that this professional fool thinks that anyone is going to believe his blatant lies. It is utterly hilarious that the idiots over there think that they are going to scare any real investor away from this stock, now that we KNOW that the company has money and someone else paying for the development of Brilacidin-UP. Remember: BRILACIDIN-UP costs the company NOTHING all the way up to its approval and commercial availability, when there will be royalty revenues.
What kind of fool would sell a share knowing that a deal like this is in place?
What kind of fool would think that an investor would sell, after this good news?
As far as the utter and complete LIE that developing Bril-UP will cost 50 million dollars -- that is one of the stupidest lies that those lowlifes have ever told. 50 million would be enough to develop the ABSSSI indication in addition to the UP and UC indications. They're not even good liars.
The fact is this: IPIX has found a great partnership with a company that has a patent-expiring drug that it needs to replace because that drug is a major source of income; yet this company is large enough, with its 3,000 employees, to be able to really run with this development and try to get it through clinical trials and to market ASAP.
And despite the lies that they are spewing at lieHUB, no one knows what the upfront payment is. This is a brilliant strategy on Leo's part, as it keeps the absolute scum that is shorting this stock from knowing the depth of the quicksand that will shortly pull them under, and it enables him to proceed with developing other forms of the drug, AND he can negotiate with any other companies he may be in discussions with, with them knowing that they cannot force him into a bad deal (because of the financing this deal is bringing).
And I'm sure it gives him satisfaction to know how distraught the shorts and bashers are.
12
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...
Continue Reading
Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...
Continue Reading
The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...
Continue Reading
The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...
Continue Reading
IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...
Continue Reading
Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...
Continue Reading
A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...
Continue Reading
Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...
Continue Reading
Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...
Continue Reading
Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...
Continue Reading
Top 5 Most Recently Viewed Articles
Transforming Security with the Fast Guard App Fast Guard Service, a prominent name in licensed security guard services, has introduced a cutting-edge solution for the construction and property management sectors. This newly enhanced Fast Guard App empowers users to swiftly order and manage essential security services, including fire watch and armed or unarmed guards,...
Continue Reading
China's Industrial Profits Accelerate in June China's industrial gains in June increased more quickly, a reflection of good economic trends despite underlying problems. Official figures revealed a 3.6% year-on-year rise in profits, against a 0.7% increase in May. Strong industry output, according to the National Bureau of Statistics (NBS), helped to explain this increase....
Continue Reading
CyberArk Celebrates a Decade Since Its IPO In a significant milestone, CyberArk, a leader in identity security, marks ten years since its Initial Public Offering (IPO) on the NASDAQ. This anniversary serves as a moment for reflection and highlights essential achievements throughout the company's growth. Ringing the NASDAQ Bell to Honor Their Journey On the day of the...
Continue Reading
Biosurgery Market Overview The global biosurgery market, currently valued at approximately US$14.96 billion, is expected to grow to a remarkable US$21.59 billion by a specified target year. This substantial growth, projected at an impressive CAGR of 6.4%, is fueled primarily by the urgent need for effective management of blood loss during surgical procedures and the rise...
Continue Reading
Overview of MIND Technology's Recent Performance MIND Technology, Inc. (NASDAQ: MIND) has recently unveiled its financial outcomes for the third quarter of fiscal 2026. The company achieved revenues amounting to approximately $9.7 million during this period. Comparative Revenue Analysis This figure reflects a notable decrease from the $13.6 million realized in the prior...
Continue Reading